Actively Recruiting

Age: 70Years +
All Genders
NCT06870617

Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)

Led by Abramson Cancer Center at Penn Medicine · Updated on 2025-10-03

150

Participants Needed

3

Research Sites

65 weeks

Total Duration

On this page

Sponsors

A

Abramson Cancer Center at Penn Medicine

Lead Sponsor

B

Bristol-Myers Squibb

Collaborating Sponsor

AI-Summary

What this Trial Is About

The use of a geriatric assessment to inform oncologic care for older persons with cancer is an evidence-based practice that improves patient-clinician communication, reduces treatment-related toxicity, and is recommended by national guidelines. However, the implementation of a geriatric assessment can be time-consuming and burdensome, leading to suboptimal use in clinical practice. Developed and endorsed by the American Society for Clinical Oncology (ASCO), the Practical Geriatric Assessment (PGA) is designed to improve clinical usability and adoption, but its implementation in real-world settings has not been evaluated. The PACE-70 study aims to evaluate PGA implementation and resultant chemotherapy dose modification among older adults with advanced cancer treated in a community setting. An exploratory aim will evaluate how the PGA, body composition (via abdominal computed tomography scan) and step count monitoring (via FitBit) correlate with chemotherapy toxicity and other clinical outcomes.

CONDITIONS

Official Title

Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)

Who Can Participate

Age: 70Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 70 years or older
  • Diagnosis of advanced or metastatic solid malignancy
  • Starting a new palliative-intent systemic therapy with a high risk of grade 3 toxicity
  • For correlative analysis: able to read and speak English and complete surveys
  • For correlative analysis: able to walk independently or with an assistive device
  • For correlative analysis: consent to participate in Fitbit monitoring, body composition analysis, and surveys
  • For correlative analysis: have a smartphone compatible with Fitbit
Not Eligible

You will not qualify if you...

  • For correlative analysis: unable to read and speak English
  • For correlative analysis: reliance on a wheelchair, ECOG performance status of 3 or higher, clinically bedbound, or unable to walk without assistance daily in the past 7 days
  • For correlative analysis: currently enrolled in a therapeutic clinical trial
  • For correlative analysis: lack of clinician consent to approach the patient

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Penn Medicine Princeton Medical Center

Princeton, New Jersey, United States, 08540

Actively Recruiting

2

Lancaster General Hospital

Lancaster, Pennsylvania, United States, 17602

Not Yet Recruiting

3

Pennsylvania Hospital

Philadelphia, Pennsylvania, United States, 19107

Actively Recruiting

Loading map...

Research Team

A

Abigail Gottschalk, MPH

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here